640,326 Shares in Upstream Bio, Inc. $UPB Bought by Hsbc Holdings PLC

Hsbc Holdings PLC purchased a new stake in Upstream Bio, Inc. (NASDAQ:UPB) during the 1st quarter, HoldingsChannel reports. The firm purchased 640,326 shares of the company’s stock, valued at approximately $5,763,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. Simplify Asset Management Inc. purchased a new stake in shares of Upstream Bio in the 1st quarter worth about $700,000. Y Intercept Hong Kong Ltd boosted its stake in shares of Upstream Bio by 2,049.2% during the 1st quarter. Y Intercept Hong Kong Ltd now owns 1,000,631 shares of the company’s stock valued at $9,006,000 after purchasing an additional 954,072 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of Upstream Bio during the fourth quarter valued at about $332,000. Invesco Ltd. increased its position in shares of Upstream Bio by 849.3% during the fourth quarter. Invesco Ltd. now owns 163,186 shares of the company’s stock valued at $4,430,000 after buying an additional 145,996 shares during the period. Finally, Empowered Funds LLC bought a new position in Upstream Bio in the fourth quarter worth about $45,000.

Wall Street Analyst Weigh In

UPB has been the subject of several research analyst reports. Mizuho lowered their price objective on shares of Upstream Bio from $51.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday, May 14th. Wall Street Zen downgraded Upstream Bio from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. JPMorgan Chase & Co. lowered Upstream Bio from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $35.00 to $8.00 in a research report on Friday, June 12th. Evercore cut Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 target price for the company. in a research note on Friday, March 27th. Finally, HC Wainwright initiated coverage on Upstream Bio in a research report on Wednesday, June 3rd. They set a “buy” rating and a $36.00 price target on the stock. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Upstream Bio currently has a consensus rating of “Hold” and a consensus target price of $33.17.

Upstream Bio Stock Down 2.9%

UPB stock opened at $6.40 on Friday. The business has a 50 day moving average of $7.24 and a 200 day moving average of $12.39. The firm has a market cap of $348.29 million, a PE ratio of -2.20 and a beta of 1.23. Upstream Bio, Inc. has a twelve month low of $5.85 and a twelve month high of $33.68.

Upstream Bio (NASDAQ:UPB) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.02). The firm had revenue of $1.03 million during the quarter, compared to the consensus estimate of $1.03 million. Upstream Bio had a negative return on equity of 43.82% and a negative net margin of 4,718.96%. On average, research analysts expect that Upstream Bio, Inc. will post -2.9 earnings per share for the current fiscal year.

Upstream Bio Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.